3 recruiting, 2 active not recruiting, 2 completed, 1 unknown. 8 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 3, Active not recruiting 2, Completed 2, Unknown 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Thyroid Cancer, Papillary: new trials by email Literature Review of Thyroid Cancer, Papillary trials Research Report on Thyroid Cancer, Papillary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. Preoperative Injection of Carbon Nanoparticles, Intraoperative Injection of Carbon Nanoparticles - Papillary Thyroid Cancer | Phase 3 | Recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 400 | 2025-01-01 | 2025-01-24 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Cabozantinib, Placebo - Differentiated Thyroid Cancer | Phase 3 | Active not recruiting | Exelixis | 187 | 2018-10-05 | 2026-10-20 |
| IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation - Thyroid Cancer, Thyroid Neoplasms | Phase 2 / Phase 3 | Active not recruiting | University College, London | 504 | 2012-06-26 | 2026-05-07 |
| Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Prophylactic central lymph node dissection - Thyroid Cancer | Phase 3 | Completed | Samsung Medical Center | 258 | 2009-01-01 | 2016-04-15 |
| High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer recombinant thyroid-stimulating hormone, Radiodine ablation without rhTSH - Head and Neck Cancer | Phase 3 | Unknown | University College, London | 438 | 2006-11-01 | 2023-12-19 |
| A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Thyrogen (thyrotropin alfa for injection) - Differentiated Thyroid Cancer | Phase 3 | Completed | Genzyme, a Sanofi Company | 61 | 2006-05-01 | 2015-03-18 |
Adenocarcinoma, Follicular (4) · Thyroid Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Erdheim-Chester Disease (2) · Glioma (2) · Hematologic Neoplasms (2) · Laryngeal Neoplasms (2) · Multiple Myeloma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Ovarian Neoplasms (2) · Thyroid Carcinoma, Anaplastic (2)
Adenocarcinoma (8) · Adenocarcinoma, Papillary (8) · Carcinoma (8) · Endocrine Gland Neoplasms (8) · Endocrine System Diseases (8) · Neoplasms, Glandular and Epithelial (8) · Thyroid Diseases (8) · Head and Neck Neoplasms (7) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Thyroid Neoplasms (5) · Adnexal Diseases (2) · Blood Protein Disorders (2) · Bronchial Neoplasms (2)
Thyrotropin Alfa (2) · Injections (1) · Sodium Iodide (1) · Thyrotropin (1) · Vemurafenib (1) · cabozantinib (1) · cobimetinib (1) · dabrafenib (1) · trametinib (1)
Cancer Research UK (2) · University College, London (2) · Exelixis (1) · Genzyme, a Sanofi Company (1) · Samsung Medical Center (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1)
United Kingdom (5) · Canada (2) · France (2) · Germany (2) · Italy (2) · South Korea (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Croatia (1) · Czechia (1)
Han-Sin Jeong, MD, PhD (1) · Matthew Krebs (1) · Matthew Krebs, Dr (1) · Ujjal K. Mallick, MD (1) · Ujjal Mallick, MBBS MS FRCR (1)
PMID 19850694, PMID 22551128, PMID 30501974, PMID 34237250, PMID 38062732, PMID 40543520
2005 (1)